Equities

ReproCell Inc

ReproCell Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)134.00
  • Today's Change-2.00 / -1.47%
  • Shares traded281.60k
  • 1 Year change-44.63%
  • Beta0.8703
Data delayed at least 20 minutes, as of May 10 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.

  • Revenue in JPY (TTM)2.51bn
  • Net income in JPY-217.49m
  • Incorporated2003
  • Employees92.00
  • Location
    ReproCell Inc9F, KDX Shin-Yokohama 381 Bldg.3-8-11, Shin-Yokohama, Kohoku-kuYOKOHAMA-SHI 222-0033JapanJPN
  • Phone+81 454753887
  • Fax+81 454741006
  • Websitehttps://reprocell.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CanBas Co Ltd (Parent)0.00-1.07bn8.31bn12.00--2.64-----64.96-64.960.00174.810.00----0.00-40.62-65.86-42.95-79.11-------1,094.10----0.00-------45.41------
Tsubota Laboratory Inc246.60m-1.07bn9.21bn10.00--8.74--37.34-42.31-42.319.9441.170.10232.2029.1624,660,200.00-44.25---64.34---182.07---432.63--1.92-417.040.1046--48.96---41.18------
TMS Co Ltd0.00-960.04m9.87bn14.00--2.86-----25.89-25.890.0085.770.00-------26.14---26.78-----------------------11.51------
Stella Pharma Corp254.09m-765.17m10.18bn46.00--3.81--40.06-25.23-25.238.3285.550.06370.04563.585,523,718.00-19.18---20.37--82.76---301.14--11.90-1,173.120.2671--128.85---1.45------
3-D Matrix Ltd3.74bn-1.06bn10.21bn108.00--16.14--2.73-14.90-14.9054.067.740.66530.46545.1934,630,130.00-18.91-57.69-23.28-77.3164.0440.76-28.43-205.342.33--0.8717--53.6358.87-29.09---7.69--
Linical Co Ltd12.52bn680.40m10.24bn759.0013.741.208.610.818130.1230.12554.28346.380.7251--3.9916,494,230.003.944.716.557.2333.1031.605.435.98--17,809.030.279345.368.326.5527.06-4.97-33.014.94
AnGes Inc152.99m-7.44bn10.67bn145.00--0.3726--69.72-39.40-39.400.8083131.520.00450.10378.401,055,069.00-21.97-28.50-25.69-33.1412.7139.42-4,861.66-6,726.821.75--0.0137--128.13-24.1749.45--12.11--
KOEI CHEMICAL COMPANY, LIMITED18.49bn62.58m11.10bn387.00177.030.51043.770.600312.7912.793,779.784,437.990.45991.304.5147,770,930.000.15573.760.2064.6824.9124.120.33856.660.53561.770.308935.807.550.4997-26.56-33.8215.6820.11
Medinet Co Ltd724.63m-1.41bn11.54bn98.00--1.97--15.93-6.31-6.313.2322.880.122411.933.617,394,143.00-23.74-21.05-24.75-22.4717.7228.75-193.90-135.4019.58--0.00--4.40-7.90-14.66---17.67--
ReproCell Inc2.51bn-217.49m11.99bn92.00--1.47--4.78-2.56-2.5629.4890.900.30084.867.4427,247,390.00-2.61-9.37-2.80-10.1143.5538.78-8.68-38.1211.94--0.00--32.1626.1046.91--28.24--
Nano Mrna Co Ltd164.39m-1.05bn12.53bn17.00--3.60--76.22-14.94-14.942.3449.400.029518.962.609,669,765.00-18.85-25.13-23.29-26.0480.6784.69-638.22-538.318.95--0.2418---23.42-4.8430.33------
RaQualia Pharma Inc1.90bn-323.66m12.94bn67.00--2.11--6.81-14.99-14.9987.98283.050.28963.133.1528,376,150.00-4.932.13-5.292.2687.1188.49-17.025.3212.35--0.05670.00-34.8520.62-144.74--0.0967--
Healios KK121.00m-3.82bn13.97bn64.00--3.00--115.46-55.07-55.071.7851.710.008--0.39291,890,625.00-25.27-23.55-35.99-28.5283.47---3,152.89-6,580.16---13.680.6756--34.44--26.04---22.00--
Oncolys Biopharma Inc63.04m-1.94bn14.40bn34.00--9.15--228.44-108.23-108.233.5475.100.02692.190.30011,854,059.00-82.64-45.75-97.13-51.8648.5560.46-3,075.14-233.665.15--0.1761---93.54-17.86-68.72--28.18--
Ohki Healthcare Holdings Co Ltd327.51bn2.35bn14.49bn576.006.050.5385.460.0443170.32170.3223,747.191,914.312.3711.644.27568,593,700.001.651.957.989.115.207.120.69620.75390.8536--0.1913.289.454.91124.49-1.16-1.279.46
Data as of May 10 2024. Currency figures normalised to ReproCell Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

1.13%Per cent of shares held by top holders
HolderShares% Held
SSgA Funds Management, Inc.as of 04 Apr 2024592.30k0.67%
Simplex Asset Management Co., Ltd.as of 04 Apr 2024400.90k0.45%
Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 2023700.000.00%
LGT Capital Partners AG (Investment Management)as of 31 May 2023600.000.00%
American Century Investment Management, Inc.as of 04 Apr 2024400.000.00%
More ▼
Data from 31 Dec 2023 - 19 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.